Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
20 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bioversys AG - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Bioversys AG - Product Pipeline Review - 2015', provides an overview of the Bioversys AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bioversys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bioversys AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bioversys AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bioversys AG's pipeline products Reasons to buy - Evaluate Bioversys AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bioversys AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bioversys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bioversys AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bioversys AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Bioversys AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Bioversys AG Snapshot 4 Bioversys AG Overview 4 Key Information 4 Key Facts 4 Bioversys AG - Research and Development Overview 5 Key Therapeutic Areas 5 Bioversys AG - Pipeline Review 6 Pipeline Products by Stage of Development 6 Pipeline Products - Monotherapy 7 Bioversys AG - Pipeline Products Glance 8 Bioversys AG - Early Stage Pipeline Products 8 Preclinical Products/Combination Treatment Modalities 8 Discovery Products/Combination Treatment Modalities 9 Bioversys AG - Drug Profiles 10 BV-6481 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 Small Molecules for Tuberculosis 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 BVNC-1 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 BVNC-2 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 BVTB-2 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Small Molecules for Multi-Drug Resistant Bacterial Infections 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Bioversys AG - Pipeline Analysis 16 Bioversys AG - Pipeline Products by Molecule Type 16 Bioversys AG - Dormant Projects 17 Bioversys AG - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 19 Disclaimer 20
List of Tables Bioversys AG, Key Information 4 Bioversys AG, Key Facts 4 Bioversys AG - Pipeline by Indication, 2015 5 Bioversys AG - Pipeline by Stage of Development, 2015 6 Bioversys AG - Monotherapy Products in Pipeline, 2015 7 Bioversys AG - Preclinical, 2015 8 Bioversys AG - Discovery, 2015 9 Bioversys AG - Pipeline by Molecule Type, 2015 16 Bioversys AG - Dormant Developmental Projects,2015 17
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.